20th century tweaked antibody platforms are not either a long term solution

https://events.flaia.org/events/fireside-chat-with-reid-rubsamen-md-scientist to view the fireside chat on demand!

20th century tweaked antibody platforms are not either a long term solution, or a good one compared with Strategic Vaccines’ 21st century revolutionary targeted killer T-cell therapeutic/vaccine, Flovid-20. Why, because Flovid-20 is a single dose, always room temp stable, and inhalation self-administered that is reliably delivered to the static nucleocapsid inside the constantly mutating Covid-19 to engage killer T-cells to continue to defeat this particular constantly mutating coronavirus characterized by the Delta variant, and Lambda gathering steam, which present as faster spreading and more lethal. Furthermore, Flovid-20 can be expected to be efficacious in the treatment of long haulers.

https://www.nature.com/articles/s41586-021-03777-9 Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization: Article Published: 08 July 2021; “The SARS-CoV-2 B.1.617 lineage was identified in October 2020 in India1–5…It has since then become dominant in some Indian regions and UK and further spread to many countries…Variant Delta was resistant to neutralization by some anti-NTD and anti-RBD mAbs including Bamlanivimab, which were impaired in binding to the Spike.”

KNOWN MATERIAL SUBSTANCE TO INVEST IN:

? Flow Pharma’s developed T-cell immunology platform in 2010 is supported by patents, 2 DOD contracts awarded in 2018 and 2019 to make a T-cell vaccine to combat Marburg, weaponized Ebola, to “protect warfighters.”

? Flow Pharma formed Strategic Vaccines to use its T-cell immunology platform to combat Covid-19 and future virulent viruses when Covid-19 emerged and retained its platform to deal with cancer and other diseases. So in the spring of 2020 was read, and applied for grants to test Flovid-20.

? Flovid-20 is made from synthetic components available in the U.S. and from trusted allies. It is always room temp stable, and 1 dose inhalation self-administered – because Flovid-20 can reliably deliver targeted killer T-cells that penetrate the outside cover of the virus to attack a static area inside to continue to defeat SARS-CoV-2 and its variants – Flovid-20 is THE revolutionary 21st C bio science platform to defeat a 21st escaped engineered deadly virus.

? Critical animal studies have shown Flovid-20 should be safe as well as efficacious. Components used in Flovid have all been used safely in other human applications. Reid Rubsamen, MD’s animal studies published in the peer reviewed journal “Vaccines” [https://www.accesswire.com/648282/Flow-Pharma-Announces-Publication-of-Pre-Clinical-Efficacy-Study-for-FlowVax-COVID-19-Vaccine] provides impressive results from animal studies distinctly superior to what Moderna and Pfizer presented to the FDA when applying for approval for Phase I testing.

? Flovid-20 is currently being produced at Oakwood Labs a GMP manufacturer, in Solon, Ohio a Cleveland suburb, 800 doses are ready for testing as a therapeutic. Oakwood Labs, one of the few labs in the US specializing in manufacturing microsphere drugs, stands ready to produce 20M doses. Further, after critical analysis from Lockheed Skunk Works, Strategic is prepared to scale

up production on machines optimized by Lockheed Skunk Works for worldwide distribution. 10 machines made in Germany from off the shelf parts, at an installed cost of $1M each, with a lead time to manufacture and ship of 4 to 6 months, can be projected to produce 120M doses over 12 months including downtime. Lockheed’s final manufacturing report is available.

? Updated financial projections are based on 10 machines producing 120M, show an EBITA for 12 months starting 12/21 ending 1/23 of: $900,959,211 @ $65 per dose. The global market - 3.7B people, demand – self-evident.

? Critically tested management is in place to make certain testing is done to rigorous standards, as well as to scale up manufacturing to be ready to scale up production immediately with FDA approval – expected to be granted under emergency circumstances as the unavoidable tragedy from the relentless Delta variant grows more palpable 24/7 – while Lambda is the next variant of concern.

? Extensive explicit support materials, including the Lockheed contract and manufacturing readiness report, DOD contracts, as well as additional due diligence materials are contained in a data room with K & L Gates, Strategic’s law firm. Management will be totally transparent, there are no bad questions.